Goals for the treatment of multiple myeloma in the era of novel agents
10.3969/j.issn.1000-8179.20140873
- VernacularTitle:新药时代多发性骨髓瘤的治疗目标
- Author:
Jian HOU
;
Xi LIU
- Publication Type:Journal Article
- Keywords:
multiple myeloma;
novel agents;
survival;
remission;
adverse effects
- From:
Chinese Journal of Clinical Oncology
2014;(13):823-826
- CountryChina
- Language:Chinese
-
Abstract:
The treatment of multiple myeloma has become possible in the era of novel agents. Novel agents have dramatically improved the response rates of multiple myeloma (MM) and have extended the survival of patients even if MM remains an incurable disease. De-termining the treatment goals of MM has become a major challenge for clinicians in the era of novel agents. Many results show the correlation between response depth and patients' survival. Complete remission (CR), stringent CR, phenotypic CR, and CRs at the molecular and PET-CT levels are being explored and becoming the goals of MM treatment. Doctors should balance efficacy with adverse effects in daily clinical practice to avoid the blind pursuit of a high and deep response rate.
